Legato Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Legato Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.41M	Buy	70,805 +7,668	+12%	+$340K	0.31%	91
2025 Q4	$2.6M	Buy	63,137 +5,496	+10%	+$220K	0.22%	113
2025 Q3	$2.24M	Buy	57,641 +7,000	+14%	+$227K	0.24%	118
2025 Q2	$1.4M	Sell	50,641 -122	-0.2%	-$3.11K	0.17%	190
2025 Q1	$1.13M	Sell	50,763 -616	-1%	-$12.7K	0.15%	220
2024 Q4	$1.02M	Sell	51,379 -15,726	-23%	-$359K	0.13%	293
2024 Q3	$1.68M	Buy	67,105 +187	+0.3%	+$4.55K	0.21%	153
2024 Q2	$1.25M	Hold	66,918	–	–	0.17%	203
2024 Q1	$1.32M	Hold	66,918	–	–	0.16%	213
2023 Q4	$1.17M	Hold	66,918	–	–	0.15%	224
2023 Q3	$1.16M	Sell	66,918 -3,143	-4%	-$53K	0.17%	203
2023 Q2	$986K	Buy	70,061 +22,751	+48%	+$305K	0.13%	265
2023 Q1	$509K	Buy	+47,310	New	+$623K	0.09%	354

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Legato Capital Management's KNSA Position: Q1 2026 in Review

Legato Capital Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 12% in Q1 2026, buying an estimated $340K and bringing the position to 70,805 shares worth $3.41M. The position accounts for 0.31% of the portfolio, ranked #91.

Legato Capital Management first reported a position in KNSA in Q1 2023 and has held it in 13 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Legato Capital Management held 70,805 shares of Kiniksa Pharmaceuticals worth $3.41M as of Q1 2026.
Legato Capital Management bought 7,668 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $340K.
Kiniksa Pharmaceuticals made up 0.31% of Legato Capital Management's portfolio in Q1 2026, its #91 holding.
Legato Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.